Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2011-11-03 Capital/Financing Update
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Unmarketable Parcel Sale Facility 6 pages 1.8MB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Cyclopharm Limited regarding the establishment of a share sale facility for holders of unmarketable parcels of shares. It explains the terms, conditions, and procedures for shareholders to sell small parcels of shares valued under $500 without brokerage fees. The document includes a letter to shareholders, details about the facility, and a form for shareholders to retain their shares if they choose. There are no financial statements, earnings data, or management discussion of financial results. The content is focused on a capital structure update related to shareholding and share sale facilitation. This fits the category of Capital/Financing Update (CAP) as it relates to changes in shareholding and capital structure facilitation, not a full financial report or regulatory filing. The document length is substantial and contains detailed information about the facility, not just a brief announcement or notice, so it is not an RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2011-11-03 English
Renewal of Debt Facility with National Australia Bank 2 pages 103.5KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 3 November 2011 from Cyclopharm Ltd, informing shareholders about the renewal of a $5.1 million debt facility with National Australia Bank. It includes details about the debt repayment schedule and background information about the company and its operations. The document is relatively short (4132 characters) and primarily serves as an update on financing activity rather than a detailed financial report or other regulatory filing. There is no indication of financial statements, audit information, or detailed management discussion. The content fits best under Capital/Financing Update (CAP) as it relates to the renewal of a debt facility and financing arrangements.
2011-11-02 English
Amended Change of Director`s Interest Notice 2 pages 209.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares disposed and held before and after the change. There is no financial performance data, earnings information, or report content. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing' filings. The document length is 3372 characters, which is consistent with a notice rather than a full report. Therefore, the appropriate classification is 'DIRS' (Director's Dealing).
2011-09-26 English
Change of Director`s Interest Notice 2 pages 209.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's personal share transactions, including the number of securities held before and after the change, the nature of the transaction (on-market sales), and the value of consideration. The document is 3297 characters long, which is relatively short and focused solely on director share dealings. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). Therefore, the correct classification is DIRS with high confidence.
2011-09-22 English
Half Yearly Report and Accounts 32 pages 223.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Cyclopharm Limited Appendix 4D - Half Year Report' and references the half year ended 30 June 2011. It contains detailed financial data including revenues, losses, segment performance, and operational updates. It includes financial statements such as Statement of Comprehensive Income, Statement of Financial Position, and Notes to the Financial Statements. The document is 15,000 characters long, indicating it is a full report rather than a brief announcement. The Appendix 4D is a regulatory form used in Australia for half-year financial reporting, which aligns with the definition of an Interim / Quarterly Report (IR). The content includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with the IR category. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2011
2011-08-30 English
Trading Update 3 pages 221.6KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Trading Update' and dated 28 July 2011. It provides a summary of financial performance comparing the first half of 2010 to 2011, including revenue growth and losses before interest and taxes. It discusses operational updates, product performance, and government policy impacts. The document references the recent AGM held on 26 May 2011 but does not contain full financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR). It is a narrative update on trading conditions and outlook rather than a formal earnings release or comprehensive financial report. The length is about 6710 characters, which is sufficient for a detailed update but the content is clearly a trading update rather than a full report. Therefore, the best classification is Capital/Financing Update (CAP), as it provides an update on financial performance and business conditions relevant to shareholders and investors but is not a formal earnings release or interim report.
2011-07-28 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.